Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo

Current Eye Research

Volumn 31, Issue 1, 2006, Pages 23-29

  Caballero, Armando R ^a   Marquart, M E ^a   O'Callaghan, Richard J ^a   Thibodeaux, B A ^b   Johnston, K H ^b   Dajcs, J J ^c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

Ciprofloxacin; Keratitis; Levofloxacin; M. abscessus; Moxifloxacin

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA; DRUG EFFECT; DRUG EFFICACY; IN VIVO STUDY; INOCULATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; TISSUE CULTURE;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; CORNEAL STROMA; CORNEAL ULCER; DISEASE MODELS, ANIMAL; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, ATYPICAL; OFLOXACIN; OPHTHALMIC SOLUTIONS; QUINOLINES; RABBITS;

EID: 31544455028     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500477321     Document Type: Article

References (52)

1. Brown-Elliott BA, Griffith DE, Wallace RJ. Newly described or emerging human species of nontuberculous mycobacteria. Infect Dis Clin N Am. 2002;16:187-202.
2. Covert TC, Rodgers MR, Reyes AL, Stelma GN. Occurrence of non-tuberculous mycobacteria in environmental samples. Appl Environ Microbiol. 1999;65:2492-2496.
3. Gangadharam PR, Lockhart JA, Awe RJ, Jenkins DE. Mycobacterial contamination through tap water [letter]. Am Rev Respir Dis. 1976;113:894.
4. Goslee S, Wolinsky E. Water as a source of potentially pathogenic mycobacteria. Am Rev Respir Dis. 1976;113:287-292.
5. Pepose JS, Holland GN, Wilhelmus KR. Ocular Infection & Immunity, 1st ed. St. Louis: Mosby; 1996:1033-1041.
6. Wolinski E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979;119:107-159.
7. Wolinski E, Rynearson TK. Mycobacteria in soil and their relation to disease-associated strains. Am Rev Respir Dis. 1968;97:1032-1037.
8. Brown-Elliott BA, Wallace RJ. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716-746.
9. Jarvis WR, and the Epidemiology Branch. Hospital Infections Program. Nosocomial outbreaks: the Centers for Disease Control's Hospital Infections Program Experience, 1980-1990. Am J Med. 1991;91:101S.
10. Wallace RJ, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Ann Rev Microbiol. 1998;2:453-490.
11. Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev. 1992;5:1-25.
12. Zhibang Y, BiXia Z, Oishan L, et al. Large scale outbreak of infection with Mycobacterium chelonae subs. abscessus after penicillin injection. J Clin Microbiol. 2002;40:2626-2628.
13. Bullington RH, Lanier JD, Font RL. Non-tubercolous mycobacterial keratitis. Arch Ophthalmol. 1992;110:519-524.
14. Freitas D, Alvarenga L, Sampaio J, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology. 2003;110:276-285.
15. Garg P, Bansal AK, Sharma S, Vemuganti GK. Bilateral infectious keratitis after laser in situ keratomilesuis: a case report and review of the literature. Ophthalmology. 2001;108:121-125.
16. Holmes GP, Bond GB, Fader RC, Fulcher HF. A cluster of cases of Mycobacterium szulgai keratitis that occurred after laser-assisted in situ keratomileusis. Clin Infect Dis. 2002;34:1039-1046.
17. Huang SCM, Soong HK, Chang JS, Liang JS. Non-tuberculous mycobacterial keratitis: a study of 22 cases. Br J Ophthalmol. 1996;80:962-968.
18. Meisler DM, Friedlander MH, Okumoto MA. Mycobacterium chelonae keratitis. Am J Ophthalmol. 1982;94:398-401.
19. Newman PE, Goodman RA, Waring III GO, et al. A cluster of cases of Mycobacterium chelonei keratitis associated with outpatient office procedures. Am J Ophthalmol. 1984;97:344-348.
20. Pushker N, Dada T, Sony P, et al. Microbial keratitis after laser in situ keratomileusis. J Refract Surg. 2002;18:280-286.
21. Yakrus MA, Mondino BJ, Holland GN. Cluster of Mycobacterium chelonae keratitis cases following laser-assisted in situ keratomileusis. Am J Ophthalmol. 2001;132:819-830.
22. Dugel PU, Holland GN, Brown HH, et al. Mycobacterium fortuitum keratitis. Ophthalmology 1988;105:661-669.
23. Ford JG, Huang AJQ, Pflugfelder SC, et al. Nontuberculous mycobacterial keratitis in south Florida. Ophthalmology. 1998;105:1652-1658.
24. Paschal JF, Holland GN, Sison RF, et al. Mycobacterium fortuitum keratitis: clinicopathogenic correlates and corticosteroid effects in an animal model. Cornea. 1992;11:493-499.
25. Reviglio V, Rodriguez ML, Picotti GS, et al. Mycobacterium chelonae keratitis following in situ keratomilesuis. J Refract Surg. 1998;14:357-360.
26. Solomon R, Donnenfeld ED, Azar DT, et al. Infectious keratitis after laser in situ keratomileusis: results of an ASCRS survey. J Cataract Refract Surg. 2003;29:2001-2006.
27. Gelender H, Carter HL, Bowman B, et al. Mycobacterium keratitis after laser in situ keratomileusis. J Refract Surg. 2000;16:191-195.
28. Abshire R, Cockrum P, Crider J, Schlech B. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther. 2004;26:191-196.
29. Saito H. Comparative antimicrobial activity of BAY 12-8039 and gatifloxacin. Drugs. 1999;58(Suppl. 2):400-401.
30. Gomez-Rodriguez AJ, Ruiz-Serrano MJ, Cuevas O. Comparative in vitro activities of moxifloxacin and linezolid with other agents against rapidly growing mycobacteria. 42nd ICAAC Meeting Abstract. 2002; Abstract E-40. San Diego, CA. Sept. 27-30.
31. Hu FR, Wang IJ. Comparison of topical antibiotics for treating Mycobacterium chelonae keratitis in a rabbit model. Curr Eye Res. 1998;17:478-482.
32. Tomioka H, Saito H, Sato K. Comparative antimycobacterial activity of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother. 1993;37:1259-1263.
33. Vacher S, Pellegrin JL, Leblanc F, et al. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin, and grepafloxacin. J Antimicrob Chemother. 1999;44:647-652.
34. Helm CJ, Holland GN, Lin R, et al. Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model. Am J Ophthalmol. 1993;116:700-707.
35. Hyon JY, Joo MJ, Hose S, et al. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis. Arch Ophthal. 2004;122:1166-1169.
36. Lin R, Holland GN, Helm CJ, et al. Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis in an animal model. Am J Ophthalmol. 1994;17:657-662.
37. Stevens RK, Holland GN, Paschal JF. Mycobacterium fortuitum keratitis. A comparison of ciprofloxacin and amikacin in an animal model. Cornea. 1992;11:500-504.
38. Yakrus MA, Hernandez SM, Floyd MM, et al. Comparison of methods for identification of Mycobacterium abscessus and M. chelonae isolates. J Clin Microbiol. 2001;39:4103-4110.
39. Kusunoki S, Ezaki T. Proposal of Mycobacterium peregrinun sp. nov. nom. rev. and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al) to species status: Mycobacterium abscessus comb. nov. Int J Syst Bacteriol. 1992;42:240-245.
40. Benz MS, Murray TG, Dubovy SR, et al. Endophthalmitis caused by Mycobacterium chelonae/abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol. 2003;121:371-373.
41. Chang MA, Sandeep J, Azar DT. 2004. Infections following laser in situ keratomileusis: an integration of the published literature. Surv Ophthal. 2004;49:269-280.
42. Giaconi J, Phan R, Ta CN. Bilateral Mycobacterium abscessus keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2002;28:887-890.
43. Sun YC, Wang IJ, Chen WL, Hu FR. Therapeutic keratectomy for Mycobacterium abscessus keratitis after LASIK. J Formos Med Assoc. 2003;102:805-807.
44. Uy HS, Nguyen QD, Durand ML, et al. Infectious crystalline keratopathy and endophthalmitis secondary to Mycobacterium abscessus in a monocular patient with Stevens-Johnson syndrome. Am J Ophthalmol. 1999;127:209-210.
45. Brown-Elliot BA, Wallace RJ, Crist CJ, et al. Comparison of in vitro activities of Gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother. 2002;46:3283-3285.
46. Hu FR. Extensive lamellar keratectomy for treatment of nontuberculous mycobacterial keratitis. Am J Ophthalmol. 1995;120:47-54.
47. Wallace RJ. Recent changes in taxonomy and disease manifestation of the rapidly growing mycobacteria. Eur J Clin Microb Infect Dis. 1994;13:953-960.
48. Woods GL, Bergman JS, Witebsky FG, et al. Multicite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microb. 1999;37:1676-1682.
49. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother. 2003;47:1958-1962.
50. Dajcs JJ, Thibodeaux BA, Marquart ME, et al. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother. 2004;48:1984-1952.
51. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved Standard M7-A6. 2003. Wayne, PA. National Committee for Clinical Laboratory Standards.
52. Robertson SM, Sanders M, Jasheway D, et al. Absorption and distribution of moxifloxacin, ofloxacin and gatifloxacin into ocular tissues and plasma following topical ocular administration to pigmented rabbits. IOVS. 2004;45:ARVO E-Abstract 4906/B230.